Femara (Letrozole) for Fertility: Side Effects, Withdrawal, and What to Expect

What Is Letrozole and Why Is It Used for Fertility?

Letrozole is an aromatase inhibitor first approved by the FDA in 1997 for postmenopausal breast cancer treatment. For fertility, it is prescribed off-label to induce ovulation. The drug blocks the enzyme aromatase, which converts androgens to estrogen. With estrogen temporarily suppressed, the pituitary gland releases more follicle-stimulating hormone (FSH), which recruits ovarian follicles and drives ovulation.

The landmark NICHD Cooperative Reproductive Medicine Network trial published in the New England Journal of Medicine in 2014 compared letrozole against clomiphene in 750 women with PCOS. Letrozole produced live-birth rates of 27.5% versus 19.1% with clomiphene, a statistically significant difference. That single trial shifted clinical practice, and ASRM's 2023 evidence-based guideline now lists letrozole as the preferred first-line agent over clomiphene for ovulation induction in PCOS.

How the Drug Is Taken in a Fertility Cycle

The standard fertility protocol is a 5-day oral course, typically starting on cycle day 3, 4, or 5. Doses range from 2.5 mg to 7.5 mg daily, titrated upward in subsequent cycles if the first dose fails to trigger a mature follicle. Because the course is short and the drug has an elimination half-life of roughly 45 hours, most of the drug has cleared by the time ovulation is expected around cycle day 14.

This pharmacokinetic timeline matters for understanding side effects. You are not taking letrozole every day for months. You take it for 5 days, your estrogen falls sharply, and then as the drug clears, estrogen rises back toward normal. That rise, not the drug itself, drives much of what women call "coming off Femara" symptoms.

The Full Side-Effect Profile During a Femara Fertility Cycle

Most side effects occur during or just after the 5-day course. They are estrogen-withdrawal effects by nature, because the drug's whole mechanism is estrogen suppression.

Hot Flashes and Night Sweats

Hot flashes are the most commonly reported side effect. In the NICHD 2014 trial, hot flashes were reported in 29.7% of women taking letrozole, compared with 45.7% in the clomiphene group. The lower rate compared with clomiphene is one reason letrozole is better tolerated overall.

For women in their reproductive years who have never experienced menopause symptoms, a hot flash during a letrozole cycle can be startling. They tend to peak on days 3 through 7 of the course and usually resolve within 3 to 5 days of taking the last pill as estrogen climbs back toward follicular-phase levels.

Mood Changes, Irritability, and Low Mood

Estrogen has direct effects on serotonin and dopamine pathways. Temporarily dropping estrogen can cause irritability, tearfulness, or a low mood that women often describe as feeling "off" or "not themselves." These mood shifts mirror what some women experience in the early days of the perimenopause transition, when estrogen fluctuates widely.

There are no large randomized trials isolating letrozole-specific psychiatric adverse events in ovulation-induction populations, which is a genuine evidence gap you deserve to know about. Data are primarily from observational reports and the NICHD trial's secondary endpoints.

Headache

Headaches are reported in roughly 10 to 24% of women using letrozole for ovulation induction, varying by dose. Women with a history of menstrual migraines are more susceptible because those headaches are typically triggered by estrogen fluctuation. The same mechanism operates here: a sharp estrogen drop during the drug course, followed by a rise during clearance, can trigger a migraine pattern.

Fatigue and Dizziness

Mild fatigue and dizziness are reported by a minority of users, largely attributed to the hypoestrogenic state during the active dosing period. These typically resolve within 24 to 48 hours of the last dose.

Ovarian Cysts

A small proportion of women develop ovarian cysts during a letrozole cycle, particularly at higher doses. Ultrasound monitoring is standard in most fertility clinics when doses exceed 5 mg, or after a prior cycle with inadequate or excessive follicular response.

Rare Side Effects

Rare but documented adverse events include:

• Bone pain or joint aching. Aromatase inhibition suppresses estrogen, which is essential for bone remodeling. Over a 5-day fertility course, this is unlikely to cause measurable bone density change. The concern is much greater for breast cancer patients on letrozole for 5 to 10 years.
• Blurred vision. Reported in case series but not confirmed as causally related in large trials. If vision changes occur during a cycle, contact your prescriber promptly.
• Hair thinning. More common with long-term use in breast cancer; rarely attributed to 5-day fertility courses, though some women report it.
• Liver enzyme elevation. Seen in long-term breast cancer dosing. Monitoring liver function is not routine in short fertility courses, but women with pre-existing liver disease should flag this with their provider.
• Thromboembolic events. No increased risk has been established for short-course letrozole in reproductive-aged women. This contrasts with clomiphene, which carries a slight estrogenic pro-coagulant concern via its estrogen-receptor antagonist rebound effect.

A practical framework for categorizing letrozole fertility side effects by timing:

| Phase | Likely Symptoms | Duration | |---|---|---| | Days 1-5 (active dosing) | Hot flashes, headache, fatigue, mood changes | Concurrent with drug | | Days 6-9 (early clearance) | Estrogen rebound symptoms: transient mood lift or mild bloating | 2-4 days post-course | | Days 10-14 (pre-ovulation) | Most symptoms resolved; some women note mid-cycle spotting or ovulatory pain | Until ovulation | | Post-ovulation luteal phase | Progesterone dominates; letrozole side effects are not active | N/A |

Is There a Letrozole Withdrawal Syndrome?

This question comes up frequently, and the honest answer requires separating two concepts.

True pharmacological dependence does not occur with letrozole. The drug has no psychoactive mechanism, no receptor downregulation that requires tapering, and no addiction potential. There is no clinical syndrome analogous to opioid withdrawal or benzodiazepine discontinuation.

Estrogen rebound does occur and is physiological, not pathological. As letrozole clears over 4 to 6 days, aromatase inhibition lifts and estrogen rises from its suppressed nadir back toward normal follicular levels. In some women, this rebound rate is fast enough to cause transient symptoms including:

• A brief recurrence of bloating or breast tenderness as estrogen climbs
• A mood shift that can go either way (some women feel notably better as estrogen returns; others report a day or two of emotional sensitivity)
• Occasional pelvic cramping as follicle growth accelerates

These symptoms are self-limited. They are not a withdrawal syndrome in any pharmacological sense, but they are a real and predictable feature of the drug's mechanism that many patient-facing resources fail to explain clearly.

What FAERS Data Show

The FDA Adverse Event Reporting System (FAERS) contains reports under letrozole for "drug withdrawal syndrome" and "drug dependence," but these originate predominantly from the oncology population using letrozole continuously for years, not from 5-day fertility courses. No published pharmacovigilance analysis has identified a distinct discontinuation syndrome specific to the ovulation-induction indication. Women searching for this information deserve to know that the FAERS signal in this context is not the same population as theirs.

Sex-Specific Physiology: How Your Hormonal Status Changes Everything

Reproductive-Age Women With PCOS

Women with PCOS already have elevated androgens and often irregular or absent ovulation. Letrozole's aromatase block lowers estrogen further from an already-variable baseline and raises FSH. Because PCOS ovaries contain more antral follicles than typical ovaries, the FSH surge can recruit multiple follicles simultaneously. This is why women with PCOS using doses above 5 mg are monitored by ultrasound to reduce multiple pregnancy risk.

Side effects in this group may be more pronounced because androgens are already elevated and the estrogen suppression is acting on a hormonal milieu that differs from normo-ovulatory women.

Women With Unexplained Infertility

In normo-ovulatory or mildly oligo-ovulatory women without PCOS, letrozole is used for controlled ovarian stimulation. Baseline estrogen is usually normal. The estrogen-dip side effects tend to be milder in this group because the hormonal swing is smaller. A 2022 Cochrane review of letrozole versus clomiphene for ovulation induction found letrozole associated with fewer vasomotor symptoms across populations.

Perimenopausal Women Attempting Fertility

Using letrozole for ovulation induction in perimenopause is off-guideline and requires specialist input. Baseline FSH is often already elevated, and adding aromatase inhibition on top of declining ovarian reserve creates an unpredictable response. Hot flashes and mood symptoms may be more severe because baseline estrogen is already low and fluctuating. Women in this life stage who are also using hormone therapy need individualized plans, as letrozole would counteract exogenous estrogen.

Cycle-Phase Pharmacology

Letrozole is always started in the early follicular phase (cycle days 3 to 7) when estrogen is naturally at its lowest. This timing is not accidental. The drug's estrogen suppression is layered on top of an already-low estrogen state, which makes the follicular-phase side effects tolerable for most women. Starting the drug in the luteal phase (when progesterone and estrogen are higher) is not standard practice and would produce more pronounced hypoestrogenic symptoms.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

This section is required reading for any woman considering or currently using letrozole for fertility.

Pregnancy

Letrozole carries FDA pregnancy category X. Category X means animal studies and/or human data show fetal risk, and the risks outweigh any benefit. Letrozole is teratogenic in animal models and must not be taken during an established pregnancy.

In the context of fertility treatment, this category is not a contradiction. The drug is taken before ovulation, during the follicular phase. If conception occurs in that same cycle, the embryo implants well after the drug has cleared. The question of whether residual drug or its effects on the follicular environment affect early embryo quality has been studied without a clear signal of harm. The NICHD 2014 trial and subsequent meta-analyses have not shown increased rates of fetal malformation in pregnancies conceived with letrozole compared with clomiphene or spontaneous conception.

However, if a cycle fails and you are unsure whether you are pregnant, do not start the next letrozole course without a negative pregnancy test. This is non-negotiable.

Lactation

Letrozole is detected in breast milk in animal studies. Human lactation transfer data are limited, but because the drug suppresses estrogen and estrogen is required for milk production, it is not used in breastfeeding women. The drug's manufacturer labeling contraindicates use during breastfeeding. Women who have recently weaned and wish to use letrozole for fertility should discuss the timing with their reproductive endocrinologist.

Contraception Requirement

Women who are sexually active and do not wish to conceive in the cycle they are taking letrozole must use reliable non-hormonal contraception (such as barrier methods) during and after the course. Hormonal contraceptives would suppress the ovulatory response the drug is trying to create. Letrozole is a teratogen; if ovulation occurs at an unexpected time and conception results while drug is still in the system, that is a risk worth preventing through clear planning.

If you are using letrozole specifically to conceive, obviously no contraception is needed, but confirming cycle timing with your provider before initiating sex is standard practice.

Who This Is Right For (and Who Should Use Caution)

Good Candidates

• Women with PCOS who are anovulatory or oligovulatory and trying to conceive
• Women with unexplained infertility undergoing timed intercourse or intrauterine insemination cycles
• Women who had side effects with clomiphene, particularly visual disturbances or thinning of the uterine lining
• Women with estrogen-receptor-positive breast cancer history who need ovulation induction (with oncology co-management)

Use With Caution or Not at All

• Women currently pregnant (contraindicated)
• Women breastfeeding (contraindicated)
• Women with severe hepatic impairment (letrozole is hepatically metabolized; dose adjustment or avoidance required)
• Women with a history of osteoporosis: even a short course causes transient estrogen suppression; bone health should be discussed with the prescriber, though 5-day courses have not been shown to measurably reduce bone density in reproductive-aged women
• Women in perimenopausal transition with very low AMH and FSH above 15 IU/L: response is unpredictable and specialist supervision is essential

Managing Side Effects: Practical Steps

Hot flashes during the 5-day course are usually mild enough to require no treatment. Staying cool, wearing breathable layers, and staying hydrated cover most cases.

For headaches, acetaminophen at standard doses is compatible with letrozole use. NSAIDs such as ibuprofen are generally avoided around ovulation time because some data suggest they may interfere with follicle rupture, though the evidence is not definitive.

Mood changes warrant acknowledgment, not minimization. The IVF and ovulation-induction experience carries psychological weight independent of the drugs. If mood symptoms are severe or persist beyond the clearance window (roughly day 10 of your cycle), speak with your provider, as this may reflect underlying anxiety or depression that the fertility process is amplifying rather than a direct drug effect.

ACOG Committee Opinion 663 recommends ultrasound monitoring when using letrozole at higher doses to track follicular response and reduce the risk of higher-order multiple pregnancies. If your clinic is not offering monitoring and you are on 5 mg or 7.5 mg, ask about it.

The Evidence Gap: What We Do Not Know

Women have been historically underrepresented in clinical pharmacology trials. Most letrozole pharmacokinetic data come from postmenopausal breast cancer populations, where body composition, hepatic function, and baseline hormonal milieu differ substantially from reproductive-aged women using 5-day fertility courses.

Specifically, we lack:

• Prospective data on letrozole's effects on mood and cognition across a full ovulation-induction cycle in reproductive-aged women
• Dose-ranging pharmacokinetic studies in women with BMI above 35, where drug metabolism may differ
• Data on cumulative side-effect burden across multiple back-to-back letrozole cycles (common in clinical practice, where women may do 3 to 6 cycles before moving to injectable gonadotropins)

The ASRM Practice Committee acknowledges that letrozole's safety profile in fertility is based on relatively short-term observational data and the NICHD trial, which ran for up to 5 cycles per participant. Longer and larger studies are needed, and this is not a reason to avoid a well-tolerated, effective drug, but it is a reason to stay in ongoing conversation with your provider about side effects as you cycle.

Frequently Asked Questions